Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

DOI record: { "DOI": "10.7759/cureus.28624", "ISSN": [ "2168-8184" ], "URL": "http://dx.doi.org/10.7759/cureus.28624", "author": [ { "affiliation": [], "family": "Kerr", "given": "Lucy", "sequence": "first" }, { "affiliation": [], "family": "Baldi", "given": "Fernando", "sequence": "additional" }, { "affiliation": [], "family": "Lobo", "given": "Raysildo", "sequence": "additional" }, { "affiliation": [], "family": "Assagra", "given": "Washington Luiz", "sequence": "additional" }, { "affiliation": [], "family": "Proença", "given": "Fernando Carlos", "sequence": "additional" }, { "affiliation": [], "family": "Chamie", "given": "Juan J", "sequence": "additional" }, { "affiliation": [], "family": "Hibberd", "given": "Jennifer A", "sequence": "additional" }, { "affiliation": [], "family": "Kory", "given": "Pierre", "sequence": "additional" }, { "affiliation": [], "family": "Cadegiani", "given": "Flavio A", "sequence": "additional" } ], "container-title": "Cureus", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 8, 31 ] ], "date-time": "2022-08-31T12:40:16Z", "timestamp": 1661949616000 }, "deposited": { "date-parts": [ [ 2022, 8, 31 ] ], "date-time": "2022-08-31T12:40:21Z", "timestamp": 1661949621000 }, "indexed": { "date-parts": [ [ 2022, 8, 31 ] ], "date-time": "2022-08-31T13:12:03Z", "timestamp": 1661951523588 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 8, 31 ] ] }, "language": "en", "link": [ { "URL": "https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "4492", "original-title": [], "prefix": "10.7759", "published": { "date-parts": [ [ 2022, 8, 31 ] ] }, "published-print": { "date-parts": [ [ 2022, 8, 31 ] ] }, "publisher": "Cureus, Inc.", "reference": [ { "DOI": "10.1093/jac/dks147", "article-title": "Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug", "author": "Mastrangelo E", "doi-asserted-by": "publisher", "journal-title": "J Antimicrob Chemother", "key": "ref1", "unstructured": "Mastrangelo E, Pezzullo M, De Burghgraeve T, et al.. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012, 67:1884-94. 10.1093/jac/dks147", "volume": "67", "year": "2012" }, { "DOI": "10.1042/BJ20120150", "article-title": "Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus", "author": "Wagstaff KM", "doi-asserted-by": "publisher", "journal-title": "Biochem J", "key": "ref2", "unstructured": "Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012, 443:851-6. 10.1042/BJ20120150", "volume": "443", "year": "2012" }, { "DOI": "10.1038/ja.2017.11", "article-title": "Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations", "author": "Crump A", "doi-asserted-by": "publisher", "journal-title": "J Antibiot (Tokyo)", "key": "ref3", "unstructured": "Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo). 2017, 70:495-505. 10.1038/ja.2017.11", "volume": "70", "year": "2017" }, { "DOI": "10.1038/s41429-020-0336-z", "article-title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen", "author": "Heidary F", "doi-asserted-by": "publisher", "journal-title": "J Antibiot (Tokyo)", "key": "ref4", "unstructured": "Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020, 73:593-602. 10.1038/s41429-020-0336-z", "volume": "73", "year": "2020" }, { "DOI": "10.1002/jcp.30055", "article-title": "Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment", "author": "Li N", "doi-asserted-by": "publisher", "journal-title": "J Cell Physiol", "key": "ref5", "unstructured": "Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021, 236:2959-75. 10.1002/jcp.30055", "volume": "236", "year": "2021" }, { "DOI": "10.1038/ncomms2924", "article-title": "The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism", "author": "Jin L", "doi-asserted-by": "publisher", "journal-title": "Nat Commun", "key": "ref6", "unstructured": "Jin L, Feng X, Rong H, et al.. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun. 2013, 4:1937. 10.1038/ncomms2924", "volume": "4", "year": "2013" }, { "DOI": "10.1016/j.fct.2019.02.005", "article-title": "Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte", "author": "Yang JS", "doi-asserted-by": "publisher", "journal-title": "Food Chem Toxicol", "key": "ref7", "unstructured": "Yang JS, Qi W, Farias-Pereira R, Choi S, Clark JM, Kim D, Park Y. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte. Food Chem Toxicol. 2019, 125:595-604. 10.1016/j.fct.2019.02.005", "volume": "125", "year": "2019" }, { "DOI": "10.1021/acsomega.8b01451", "article-title": "Ivermectin promotes peripheral nerve regeneration during wound healing", "author": "Cairns DM", "doi-asserted-by": "publisher", "journal-title": "ACS Omega", "key": "ref8", "unstructured": "Cairns DM, Giordano JE, Conte S, Levin M, Kaplan DL. Ivermectin promotes peripheral nerve regeneration during wound healing. ACS Omega. 2018, 3:12392-402. 10.1021/acsomega.8b01451", "volume": "3", "year": "2018" }, { "DOI": "10.1038/s41569-020-0360-5", "article-title": "COVID-19 and the cardiovascular system", "author": "Zheng YY", "doi-asserted-by": "publisher", "journal-title": "Nat Rev Cardiol", "key": "ref9", "unstructured": "Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020, 17:259-60. 10.1038/s41569-020-0360-5", "volume": "17", "year": "2020" }, { "DOI": "10.1016/j.ebiom.2017.09.022", "article-title": "Antihypertrophic effects of small molecules that maintain mitochondrial ATP levels under hypoxia", "author": "Nagai H", "doi-asserted-by": "publisher", "journal-title": "EBioMedicine", "key": "ref10", "unstructured": "Nagai H, Satomi T, Abiru A, et al.. Antihypertrophic effects of small molecules that maintain mitochondrial ATP levels under hypoxia. EBioMedicine. 2017, 24:147-58. 10.1016/j.ebiom.2017.09.022", "volume": "24", "year": "2017" }, { "DOI": "10.1016/j.chom.2020.05.008", "article-title": "Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19", "author": "Park A", "doi-asserted-by": "publisher", "journal-title": "Cell Host Microbe", "key": "ref11", "unstructured": "Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020, 27:870-8. 10.1016/j.chom.2020.05.008", "volume": "27", "year": "2020" }, { "DOI": "10.1007/s00011-008-8007-8", "article-title": "Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice", "author": "Zhang X", "doi-asserted-by": "publisher", "journal-title": "Inflamm Res", "key": "ref12", "unstructured": "Zhang X, Song Y, Ci X, et al.. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008, 57:524-9. 10.1007/s00011-008-8007-8", "volume": "57", "year": "2008" }, { "DOI": "10.1038/s41429-021-00491-6", "article-title": "The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review", "author": "Zaidi AK", "doi-asserted-by": "publisher", "journal-title": "J Antibiot (Tokyo)", "key": "ref13", "unstructured": "Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review. J Antibiot (Tokyo). 2022, 75:60-71. 10.1038/s41429-021-00491-6", "volume": "75", "year": "2022" }, { "DOI": "10.1038/s41418-020-00633-7", "article-title": "An aberrant STAT pathway is central to COVID-19", "author": "Matsuyama T", "doi-asserted-by": "publisher", "journal-title": "Cell Death Differ", "key": "ref14", "unstructured": "Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020, 27:3209-25. 10.1038/s41418-020-00633-7", "volume": "27", "year": "2020" }, { "DOI": "10.1158/0008-5472.CAN-15-2887", "article-title": "Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer", "author": "Dou Q", "doi-asserted-by": "publisher", "journal-title": "Cancer Res", "key": "ref15", "unstructured": "Dou Q, Chen HN, Wang K, et al.. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 2016, 76:4457-69. 10.1158/0008-5472.CAN-15-2887", "volume": "76", "year": "2016" }, { "DOI": "10.4049/jimmunol.1700965", "article-title": "ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages", "author": "Layhadi JA", "doi-asserted-by": "publisher", "journal-title": "J Immunol", "key": "ref16", "unstructured": "Layhadi JA, Turner J, Crossman D, Fountain SJ. ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages. J Immunol. 2018, 200:1159-68. 10.4049/jimmunol.1700965", "volume": "200", "year": "2018" }, { "article-title": "The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug", "author": "Juarez M", "journal-title": "Am J Cancer Res", "key": "ref17", "unstructured": "Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018, 8:317-31.", "volume": "8", "year": "2018" }, { "DOI": "10.1186/s10020-020-00172-4", "article-title": "Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?", "author": "Andersson U", "doi-asserted-by": "publisher", "journal-title": "Mol Med", "key": "ref18", "unstructured": "Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?. Mol Med. 2020, 26:42. 10.1186/s10020-020-00172-4", "volume": "26", "year": "2020" }, { "DOI": "10.1007/s00011-011-0307-8", "article-title": "Anti-inflammatory effects of ivermectin in mouse model of allergic asthma", "author": "Yan S", "doi-asserted-by": "publisher", "journal-title": "Inflamm Res", "key": "ref19", "unstructured": "Yan S, Ci X, Chen N, et al.. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res. 2011, 60:589-96. 10.1007/s00011-011-0307-8", "volume": "60", "year": "2011" }, { "DOI": "10.1007/s43440-020-00195-y", "article-title": "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes", "author": "Kaur H", "doi-asserted-by": "publisher", "journal-title": "Pharmacol Rep", "key": "ref20", "unstructured": "Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021, 73:736-49. 10.1007/s43440-020-00195-y", "volume": "73", "year": "2021" }, { "DOI": "10.1038/s41429-021-00430-5", "article-title": "The mechanisms of action of ivermectin against SARS-CoV-2: an evidence-based clinical review article", "author": "Zaidi AK", "doi-asserted-by": "publisher", "journal-title": "J Antibiot (Tokyo)", "key": "ref21", "unstructured": "Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2: an evidence-based clinical review article. J Antibiot (Tokyo). 2022, 75:122. 10.1038/s41429-021-00430-5", "volume": "75", "year": "2022" }, { "DOI": "10.1101/2020.11.30.20236570", "article-title": "The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence. [PREPRINT]", "author": "Kalfas S", "doi-asserted-by": "publisher", "journal-title": "medRxiv", "key": "ref22", "unstructured": "Kalfas S, Visvanathan K, Chan K Drago J. The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence. [PREPRINT]. medRxiv. 2020, 10.1101/2020.11.30.20236570", "year": "2020" }, { "DOI": "10.1371/journal.pone.0247163", "article-title": "Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study", "author": "Behera P", "doi-asserted-by": "publisher", "journal-title": "PLoS One", "key": "ref23", "unstructured": "Behera P, Patro BK, Singh AK, et al.. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study. PLoS One. 2021, 16:e0247163. 10.1371/journal.pone.0247163", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.ijantimicag.2020.106248", "article-title": "A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin", "author": "Hellwig MD", "doi-asserted-by": "publisher", "journal-title": "Int J Antimicrob Agents", "key": "ref24", "unstructured": "Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents. 2021, 57:106248. 10.1016/j.ijantimicag.2020.106248", "volume": "57", "year": "2021" }, { "DOI": "10.7759/cureus.21272", "article-title": "Ivermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching", "author": "Kerr L", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "ref25", "unstructured": "Kerr L, Cadegiani FA, Baldi F, et al.. Ivermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching. Cureus. 2022, 14:e21272. 10.7759/cureus.21272", "volume": "14", "year": "2022" }, { "key": "ref26", "unstructured": "Coronavirus epidemiological data - State of Santa Catarina. (2022). Accessed. July 8, 2022: https://itajai.sc.gov.br/noticias/59/boletins-coronavirus." }, { "article-title": "Trend in the mortality and incidence from AIDS in Itajaí (Santa Catarina) between 1990 and 2005. (Article in Portuguese)", "author": "Boing AF", "journal-title": "Arch Catarin Med", "key": "ref27", "unstructured": "Boing AF, Lunardon C. Trend in the mortality and incidence from AIDS in Itajaí (Santa Catarina) between 1990 and 2005. (Article in Portuguese). Arch Catarin Med. 2009, 38:59-65.", "volume": "38", "year": "2009" }, { "key": "ref28", "unstructured": "HIV/AIDS and port workers. a resource pack for unions. (2013). Accessed: January 22, 2021: https://www.itfglobal.org/sites/default/files/resources-files/HIV_AIDS_portworkers.pdf." }, { "DOI": "10.1086/715158", "article-title": "Hospital avoidance and unintended deaths during the COVID-19 pandemic", "author": "Zhang J", "doi-asserted-by": "publisher", "journal-title": "Am J Health Econ", "key": "ref29", "unstructured": "Zhang J. Hospital avoidance and unintended deaths during the COVID-19 pandemic. Am J Health Econ. 2021, 7:405-26. 10.1086/715158", "volume": "7", "year": "2021" }, { "DOI": "10.1002/cpt.2083", "article-title": "Randomized controlled trials versus real world evidence: neither magic nor myth", "author": "Eichler HG", "doi-asserted-by": "publisher", "journal-title": "Clin Pharmacol Ther", "key": "ref30", "unstructured": "Eichler HG, Pignatti F, Schwarzer-Daum B, et al.. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021, 109:1212-8. 10.1002/cpt.2083", "volume": "109", "year": "2021" }, { "DOI": "10.1002/cpt.1210", "article-title": "Using real-world data to extrapolate evidence from randomized controlled trials", "author": "Wang SV", "doi-asserted-by": "publisher", "journal-title": "Clin Pharmacol Ther", "key": "ref31", "unstructured": "Wang SV, Schneeweiss S, Gagne JJ, Evers T, Gerlinger C, Desai R, Najafzadeh M. Using real-world data to extrapolate evidence from randomized controlled trials. Clin Pharmacol Ther. 2019, 105:1156-63. 10.1002/cpt.1210", "volume": "105", "year": "2019" }, { "DOI": "10.1002/cpt.857", "article-title": "When and how can real world data analyses substitute for randomized controlled trials?", "author": "Franklin JM", "doi-asserted-by": "publisher", "journal-title": "Clin Pharmacol Ther", "key": "ref32", "unstructured": "Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials?. Clin Pharmacol Ther. 2017, 102:924-33. 10.1002/cpt.857", "volume": "102", "year": "2017" } ], "reference-count": 32, "references-count": 32, "relation": {}, "resource": { "primary": { "URL": "https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Aerospace Engineering" ], "subtitle": [], "title": "Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects", "type": "journal-article" }